Zacks Investment Research·Aug 21, 2026
Here's Why You Should Retain Inogen Stock in Your Portfolio for NowINGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Inogen faces a challenging fundamental outlook as its direct-to-consumer sales model struggles to generate consistent profitability, evidenced by persistent operating losses and a deceleration in revenue growth to 3.4% in 2026Q1. While the company maintains a ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.14+8.7% vs -$0.15 | $95M-0.2% vs $95M |
Q2 2026 May 7, 2026 | -$0.30-25.0% vs -$0.24 | $85M+3.4% vs $82M |
Q1 2026 Feb 24, 2026 | -$0.26+27.8% vs -$0.36 | $82M-3.9% vs $85M |
Q4 2025 Nov 5, 2025 | -$0.20+9.1% vs -$0.22 | $92M+4.3% vs $89M |
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Benchmark INGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Inogen, Inc. (INGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.09 | $137.81M | -5.99 | 3.86% | -6.52% | -12.43% | — | |
| $99.97 | $6.51B | 29.32 | 0.5% | 17.69% | 23.27% | — | |
| $73.30 | $3.74B | 34.25 | 7.03% | 11.72% | 29.93% | — | |
| $36.78 | $767.54M | 14.60 | 3.21% | 4.88% | 13.43% | — | |
| $118.71 | $22.91B | 10.68 | -3.54% | 11.62% | 14.73% | — | |
| $2.00 | $84.47M | -1.50 | 8.01% | -55.03% | -96.66% | — |
Inogen, Inc. (INGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Inogen, Inc. (INGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 1, 2026·SEC
Jun 11, 2026·SEC
Get notified when INGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Inogen, Inc. (INGN) stock FAQ — growth, dividends, profitability & financials explained
Inogen, Inc. (INGN) reported $354.3M in revenue for fiscal year 2025. This represents a 1057% increase from $30.6M in 2011.
Inogen, Inc. (INGN) grew revenue by 3.9% over the past year. Growth has been modest.
Inogen, Inc. (INGN) reported a net loss of $24.6M for fiscal year 2025.
Inogen, Inc. (INGN) has a return on equity (ROE) of -12.4%. Negative ROE indicates the company is unprofitable.
Inogen, Inc. (INGN) had negative free cash flow of $9.7M in fiscal year 2025, likely due to heavy capital investments.
